Genprex Inc (NASDAQ: GNPX) recently released a very important piece of news. In a press release, the company announced that it has joined the Health Discovery Building at Dell Medical School in order to drive further medical innovation. Today, we’ll talk about:
- The news;
- what this means for GNPX;
- and what we’ll be watching for ahead.
GNPX Announces A Collaboration With Dell Medical School
As mentioned above, Genprex recently announced a big piece of news. The company, a clinical stage biotechnology company with a focus on gene therapy and the development of immunogene therapy in the oncology space, announced a collaboration with Dell Medical School. Dell Medical School is an extension of The University of Texas at Austin. In the release, GNPX said that the collaboration will lead to the establishment of executive offices at the school’s Health Discovery Building, joining the WorkSpaces @ Texas Health CoLab. The idea here is to establish a robust health innovation ecosystem. In a statement, Dr. Ruben Rathnasingham, Managing Director of the Texas Health CoLab, had the following to offer:
Texas Health CoLab combines world-class research and technology capabilities, along with passionate people and space for multi-disciplinary teamwork, and we’re delighted to welcome Genprex to our collaborative space… We share a common goal to advance innovative research and technologies that may impact some of the greatest challenges facing health care today.
The above statement was followed up by Rodney Varner, Chairman and CEO at GNPX, had the following to offer:
We are committed to establishing and growing strategic partnerships that complement and strengthen our work across oncology and gene therapy… We are eager to join this group of respected and talented peers at the Health Discovery Building as we expand on our pivotal work to date, which has positioned the Company for continued growth in 2018 and beyond.
Why This Is Important For The Company
The collaboration with the Dell Medical School is a strong step in the right direction for GNPX. At the end of the day, the company is establishing offices in one of the most respected medical schools in the nation. This will open the door to resources that will likely drive medical innovation and opportunities for all involved.
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on GNPX. In particular, we’re interested in following the story surrounding the company’s work with the Dell Medical School as well as the company’s work surrounding Oncoprex, a treatment that could become a revolutionary change in the oncology space. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!